Antifibrotic Agent Pirfenidone Protects against Development of Radiation-Induced Pulmonary Fibrosis in a Murine Model
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Radiation-induced complications of the respiratory system are a common side effect of thoracic radiotherapy with no viable treatment option. Here, we investigated the potential therapeutic effect of the orphan drug pirfenidone for treating radiation-induced pulmonary fibrosis. C57BL/6 mice received a single fraction of 16 Gy to the thorax and were subsequently treated with 300 mg/kg/day pirfenidone for four weeks. Survival and body weight of the mice were quantified. Micro-CT in vivo lung imaging was performed to dynamically observe the developmental process of pulmonary fibrosis. The lungs were excised at the end of the experiment and evaluated for histological changes. Compared to the irradiated mice that received no pirfenidone, mice treated with pirfenidone after irradiation had an extended median survival time (>140 days vs. 73 days, P < 0.01). The accumulation of collagen and fibrosis in lung tissues after irradiation was decreased with pirfenidone treatment. Pirfenidone also reduced the expression of TGF-β1 and phosphorylation of Smad3 in lung tissues. The dose level of Pirfenidone used in this study attenuated pulmonary fibrosis and prolonged the life span of irradiated mice. It may offer a promising approach to treat or minimize radiation-induced pulmonary fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Conte, E., Gili, E., Fagone, E., Fruciano, M., Iemmolo, M., & Vancheri, C. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.02.014 · Cited by 368
The role of mouse strain differences in the susceptibility to fibrosis: a systematic review
Walkin, L., Herrick, S. E., Summers, A., Brenchley, P. E., Hoff, C. M., Korstanje, R., & Margetts, P. J. (2013) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-6-18 · Cited by 160
Cited by
Pirfenidone: Molecular mechanisms and potential clinical applications in lung disease
Ruwanpura, S. M., Thomas, B. J., & Bardin, P. G. (2020) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2019-0328tr · Cited by 317
Ying, H., Fang, M., Hang, Q. Q., Chen, Y., Qian, X., & Chen, M. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16821 · Cited by 131
Inhibition of TGFβ1 activation prevents radiation-induced lung fibrosis
Yi, M., Yuan, Y., Ma, L., Li, L., Qin, W., Wu, B., Zheng, B., Liao, X., Hu, G., & Liu, B. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1546 · Cited by 33
Self-citationChen, M. C., Korth, C. C., Harnett, M. D., Elenko, E., & Lickliter, J. D. (2022) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1040 · Cited by 18
Idiopathic Pulmonary Fibrosis: Where do We Stand and How Far to Go?
Singh, V., Ulasov, I., Gupta, S., Singh, A., Roy, V. K., & Kharwar, R. K. (2024) · Discovery Medicine · doi:10.24976/discov.med.202436180.3 · Cited by 17
Metadata
- Authors
- Qin, W., Liu, B., Yi, M., Li, L., Tang, Y., Wu, B., & Yuan, X.
- Venue
- Radiation Research
- Publisher
- Radiation Research Society
- Published
- 2018-07-27
- Volume
- 190
- Issue
- 4
- Pages
- 396
- ISSN
- 0033-7587 (ISSN-L)
- OpenAlex
- W2884468211
- Cited by
- 48
- References
- 3
- FWCI
- 3.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antifibrotic Agent Pirfenidone Protects against Development of Radiation-Induced Pulmonary Fibrosis in a Murine Model. https://app.cochat.ai/papers/10.1667/rr15017.1
- The paper
- Qin, W., Liu, B., Yi, M., Li, L., Tang, Y., Wu, B., & Yuan, X. (2018). Antifibrotic Agent Pirfenidone Protects against Development of Radiation-Induced Pulmonary Fibrosis in a Murine Model. Radiation Research. https://doi.org/10.1667/rr15017.1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.